Tezepelumab in severe asthma: a profile of its use
Funding The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest Yahiya Y. Syed is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability not applicable
Additional information about this Adis Drug Review can be found here
Tezepelumab (tezepelumab-ekko; TEZSPIRE®), a first-in-class monoclonal antibody targeting thymic stromal lymphopoietin, represents a novel, effective and generally well tolerated treatment option for patients with severe asthma across a wide range of phenotypes. In randomized, double-blind, phase 2 (PATHWAY) and phase 3 (NAVIGATOR) trials, subcutaneous tezepelumab demonstrated a significant reduction in annualized asthma exacerbation rate among patients with severe uncontrolled asthma. The efficacy was seen across a broad range of patients with different asthma endotypes and phenotypes, including eosinophilic and noneosinophilic asthma, allergic asthma, and type-2 low asthma. The efficacy was sustained over up to 104 weeks. Tezepelumab is generally well tolerated, with the most common adverse reactions being pharyngitis, arthralgia and back pain.
© Springer Nature Switzerland AG 2023